Cannabis in pregnancy triggers brain protein changes in fetuses

Researchers investigated how cannabis use during pregnancy affects the developing fetal brain by examining molecular markers in maternal blood and fetal brain tissue. The study found that maternal cannabis exposure was associated with significant changes in key brain proteins including CB1R (cannabinoid receptor 1) and D2R (dopamine receptor 2), which play crucial roles in brain development, motivation, and motor control. These changes were particularly pronounced in male fetuses. Additionally, the team identified 21 microRNAs with altered expression patterns, with 14 showing decreased levels and 6 showing increased levels—molecular switches that regulate gene expression and influence neurodevelopment.

The study's most innovative aspect is the discovery that fetal brain-derived extracellular vesicles in maternal blood could serve as biomarkers for monitoring cannabis effects on the developing brain during pregnancy. These tiny packets carrying proteins and genetic information from the fetal brain can be isolated from a simple maternal blood test, potentially allowing doctors to track fetal brain health non-invasively. Many of the affected molecular pathways are linked to conditions like attention disorders and cognitive impairment, suggesting prenatal cannabis exposure may have lasting neurodevelopmental consequences.

While this research doesn't yet prove that these molecular changes will cause health problems, it opens the door to future clinical applications where pregnant women could be monitored for cannabis-related fetal brain changes and outcomes could be tracked after birth to understand the real-world impact on child development.